Kenvue Inc.
Kenvue Reports Q3 2025 Financial Results and Announces Executive Changes
Summary
Kenvue Inc. announced its financial results for the fiscal third quarter ended September 28, 2025, reporting a 3.5% decrease in net sales and a 4.4% decline in organic sales compared to the prior year. Diluted earnings per share (EPS) were $0.21, with adjusted diluted EPS at $0.28. The company affirmed its full-year 2025 outlook and also announced key leadership appointments, including the permanent appointment of Kirk Perry as Chief Executive Officer and the creation of a new Chief Digital and Marketing Officer role. Additionally, Kenvue entered into a definitive merger agreement with Kimberly-Clark.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement